Celltrion completes Phase III clinical trials for CT-6P

Published: 2013-06-07 06:56:00

Updated: 2013-06-07 06:56:00

Celltrion on Tuesday said that it has completed Phase III trials for its biosimilar candidate CT-P6 to demonstrate he comparable bioequivalence, efficacy and safety of CT-P6 to the reference drug.

CT-P6 is intended to be a biosimilar of Roche’s breast cancer blockbuster Herceptin (trastuzumab)...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK